180 related articles for article (PubMed ID: 16168106)
1. Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.
von Minckwitz G; Harder S; Hövelmann S; Jäger E; Al-Batran SE; Loibl S; Atmaca A; Cimpoiasu C; Neumann A; Abera A; Knuth A; Kaufmann M; Jäger D; Maurer AB; Wels WS
Breast Cancer Res; 2005; 7(5):R617-26. PubMed ID: 16168106
[TBL] [Abstract][Full Text] [Related]
2. Antitumor effect of an HER2-specific antibody-toxin fusion protein on human prostate cancer cells.
Wang L; Liu B; Schmidt M; Lu Y; Wels W; Fan Z
Prostate; 2001 Apr; 47(1):21-8. PubMed ID: 11304726
[TBL] [Abstract][Full Text] [Related]
3. Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2.
Azemar M; Djahansouzi S; Jäger E; Solbach C; Schmidt M; Maurer AB; Mross K; Unger C; von Minckwitz G; Dall P; Groner B; Wels WS
Breast Cancer Res Treat; 2003 Dec; 82(3):155-64. PubMed ID: 14703062
[TBL] [Abstract][Full Text] [Related]
4. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2.
Schmidt M; McWatters A; White RA; Groner B; Wels W; Fan Z; Bast RC
Gynecol Oncol; 2001 Feb; 80(2):145-55. PubMed ID: 11161852
[TBL] [Abstract][Full Text] [Related]
6. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin.
Altenschmidt U; Schmidt M; Groner B; Wels W
Int J Cancer; 1997 Sep; 73(1):117-24. PubMed ID: 9334818
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
9. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
Uherek C; Tonn T; Uherek B; Becker S; Schnierle B; Klingemann HG; Wels W
Blood; 2002 Aug; 100(4):1265-73. PubMed ID: 12149207
[TBL] [Abstract][Full Text] [Related]
10. Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor.
Mahmud H; Dälken B; Wels WS
Mol Cancer Ther; 2009 Jun; 8(6):1526-35. PubMed ID: 19509241
[TBL] [Abstract][Full Text] [Related]
11. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
12. Biotechnological and gene therapeutic strategies in cancer treatment.
Wels W; Moritz D; Schmidt M; Jeschke M; Hynes NE; Groner B
Gene; 1995 Jun; 159(1):73-80. PubMed ID: 7607575
[TBL] [Abstract][Full Text] [Related]
13. A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor.
Schmidt M; Hynes NE; Groner B; Wels W
Int J Cancer; 1996 Feb; 65(4):538-46. PubMed ID: 8621240
[TBL] [Abstract][Full Text] [Related]
14. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
15. Understanding structural/functional properties of immunoconjugates for cancer therapy by computational approaches.
Arcangeli C; Cantale C; Galeffi P; Gianese G; Paparcone R; Rosato V
J Biomol Struct Dyn; 2008 Aug; 26(1):35-48. PubMed ID: 18533724
[TBL] [Abstract][Full Text] [Related]
16. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.
Meier R; Piert M; Piontek G; Rudelius M; Oostendorp RA; Senekowitsch-Schmidtke R; Henning TD; Wels WS; Uherek C; Rummeny EJ; Daldrup-Link HE
Nucl Med Biol; 2008 Jul; 35(5):579-88. PubMed ID: 18589302
[TBL] [Abstract][Full Text] [Related]
17. Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells.
Maurer-Gebhard M; Schmidt M; Azemar M; Altenschmidt U; Stöcklin E; Wels W; Groner B
Cancer Res; 1998 Jun; 58(12):2661-6. PubMed ID: 9635594
[TBL] [Abstract][Full Text] [Related]
18. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
19. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
Schmidt M; Vakalopoulou E; Schneider DW; Wels W
Br J Cancer; 1997; 75(11):1575-84. PubMed ID: 9184171
[TBL] [Abstract][Full Text] [Related]
20. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]